Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Bartter-like Syndrome Induced By Tacrolimus in a Renal Transplanted Boy: A Case Report

Author(s): Raphael Figuiredo Dias, Mateus da Costa Monteiro, Renata Aguiar Menezes Silva, Mirella Monique Lana Diniz and Ana Cristina Simões e Silva*

Volume 18, Issue 3, 2023

Published on: 22 August, 2022

Page: [398 - 403] Pages: 6

DOI: 10.2174/1574886317666220518085725

Price: $65

Abstract

Background: Losing-salt tubulopathies, such as Bartter syndrome, are rare and usually inherited due to mutations of tubular reabsorption channels of the nephrons. Despite its scarcity, some cases of acquired losing-salt tubulopathies have been described. In this case report, we discuss the main aspects of Bartter syndrome and present a rare pediatric case of probable tacrolimusinduced Bartter-like syndrome in a renal transplanted boy.

Case Presentation: A ten-year-old male patient with end-stage renal disease due to endo and extra capillary glomerulonephritis was submitted to renal transplantation from a deceased donor. The post-operatory evolution was satisfactory with normalization of serum creatinine levels, mild hypertension, and the absence of metabolic disorders. The immunosuppression protocol included tacrolimus (0.3 mg/kg/day), mycophenolate (455 mg/m2/day) and prednisone (0.5 mg/kg/day). Two months later, the patient was hospitalized due to vomiting, dehydration, intense hypokalemia (1.3 mEq/L), hyponatremia (125 mEq/L), and hypochloremia (84 mmol/L). During hospitalization, he evolved with polydipsia (3000 mL/day) and polyuria (120-160 mL/m2/h) associated with major elevation of urinary potassium excretion, hypercalciuria, mild metabolic alkalosis, hyperfiltration, and proteinuria. The tacrolimus dose was reduced under the suspicion of tubular dysfunction, leading to a better metabolic profile. However, the patient developed a Banff IIb graft rejection, which required pulse therapy and elevation of tacrolimus and mycophenolate doses. Recovery of renal function parameters occurred, but the metabolic disorders worsened following tacrolimus dose elevation. The patient required chronic potassium, chloride, and sodium replacement.

Conclusion: After administering immunosuppressive medications, physicians should be aware of the possibility of Bartter-like or other losing-salt tubulopathies syndromes that can affect metabolic homeostasis. The suspicion must always be considered in the case of a transplanted patient who presents dehydration and hydroelectrolytic disorders right after the commencement of nephrotoxic immunosuppressive drugs, including tacrolimus and cyclosporine.

Keywords: Bartter-like Syndrome, tacrolimus, kidney transplant, pediatric nephrology, hydroelectrolytic disorder, hypercalciuria.

« Previous Next »
[1]
Bartter FC, Pronove P, Gill JR Jr, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 1962; 33: 811-28.
[http://dx.doi.org/10.1016/0002-9343(62)90214-0] [PMID: 13969763]
[2]
Allapathi D, Alvarez D, Dave-Sharma S, Prosper G, Sharma J. Severe failure to thrive in infant. Clin Pediatr 2008; 47(7): 698-700.
[http://dx.doi.org/10.1177/0009922808318345] [PMID: 18539871]
[3]
Brambilla I, Poddighe D, Semeria Mantelli S, Guarracino C, Marseglia GL. Bartter syndrome and growth hormone deficiency: Three siblings with a novel CLCNKB mutation. Pediatr Int 2019; 61(2): 193-7.
[http://dx.doi.org/10.1111/ped.13726] [PMID: 30387909]
[4]
Alhammadi AH, Khalifa M, Alnaimi L. An infant with poor weight gain and hypochloremic metabolic alkalosis: A case report. Int J Gen Med 2014; 7: 389-91.
[http://dx.doi.org/10.2147/IJGM.S66550] [PMID: 25114583]
[5]
Mrad FCC, Soares SBM, de Menezes Silva LAW, dos Anjos Menezes PV, Simões-e-Silva AC. Bartter’s syndrome: Clinical findings, genetic causes and therapeutic approach. World J Pediatr 2020.
[6]
Kömhoff M, Laghmani K. MAGED2: A novel form of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 2018; 27(4): 323-8.
[http://dx.doi.org/10.1097/MNH.0000000000000422] [PMID: 29677005]
[7]
Hussain S, Tarar SH, Al-Muhaizae M. A rare disorder with common clinical presentation: Neonatal bartter syndrome. J Coll Physicians Surg Pak 2015; 25 (Suppl. 1): S58-60.
[8]
Andrini O, Keck M, Briones R, Lourdel S, Vargas-Poussou R, Teulon J. ClC-K chloride channels: Emerging pathophysiology of Bartter syndrome type 3. Am J Physiol Renal Physiol 2015; 308(12): F1324-34.
[http://dx.doi.org/10.1152/ajprenal.00004.2015] [PMID: 25810436]
[9]
Fulchiero R, Seo-Mayer P. Bartter syndrome and gitelman syndrome. Pediatr Clin North Am 2019; 66(1): 121-34.
[http://dx.doi.org/10.1016/j.pcl.2018.08.010] [PMID: 30454738]
[10]
Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Emma F, Goldstein SL, Eds. Pediatric Nephrology. Berlin, Heidelberg: Springer Berlin Heidelberg 2016.
[http://dx.doi.org/10.1007/978-3-662-43596-0]
[11]
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351(26): 2715-29.
[http://dx.doi.org/10.1056/NEJMra033540] [PMID: 15616206]
[12]
Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012; 25(3): 269-75.
[http://dx.doi.org/10.5301/jn.5000174] [PMID: 22573529]
[13]
Damiano S, Scanni R, Ciarcia R, Florio S, Capasso G. Regulation of sodium transporters in the kidney during cyclosporine treatment. J Nephrol 2010; 23 (Suppl. 16): S191-8.
[PMID: 21170880]
[14]
Hadchouel J, Delaloy C, Fauré S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J Am Soc Nephrol 2006; 17(1): 208-17.
[http://dx.doi.org/10.1681/ASN.2005030314] [PMID: 16221868]
[15]
Chou CL, Chen YH, Chau T, Lin SH. Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 2005; 329(3): 144-9.
[http://dx.doi.org/10.1097/00000441-200503000-00007] [PMID: 15767821]
[16]
Chen YS, Fang HC, Chou KJ, et al. Gentamicin-induced Bartter-like syndrome. Am J Kidney Dis 2009; 54(6): 1158-61.
[http://dx.doi.org/10.1053/j.ajkd.2009.07.016] [PMID: 19765870]
[17]
Workeneh B, Sangsiraprapha W, Addison D, Longfield E. A novel case of persistent Bartters-like syndrome associated with gentamicin exposure. Saudi J Kidney Dis Transpl 2013; 24(1): 144-6.
[http://dx.doi.org/10.4103/1319-2442.106314] [PMID: 23354214]
[18]
Singh J, Patel ML, Gupta KK, Pandey S, Dinkar A. Acquired Bartter syndrome following gentamicin therapy. Indian J Nephrol 2016; 26(6): 461-3.
[http://dx.doi.org/10.4103/0971-4065.177206] [PMID: 27942182]
[19]
Landau D, Kher KK. Gentamicin-induced Bartter-like syndrome. Pediatr Nephrol 1997; 11(6): 737-40.
[http://dx.doi.org/10.1007/s004670050378] [PMID: 9438655]
[20]
Cakir U, Alan S, Zeybek C, et al. Acquired bartter-like syndrome associated with colistin use in a preterm infant. Ren Fail 2013; 35(3): 411-3.
[http://dx.doi.org/10.3109/0886022X.2012.761084] [PMID: 23342992]
[21]
Tabish M, Mahendran M, Ray A, Vikram NK. Colistin-induced acquired Bartter-like syndrome: An unusual cause of meltdown. BMJ Case Rep 2020; 13(2): e232630.
[http://dx.doi.org/10.1136/bcr-2019-232630] [PMID: 32029515]
[22]
Chrispal A, Boorugu H, Prabhakar AT, Moses V. Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia. J Postgrad Med 2009; 55(3): 208-10.
[http://dx.doi.org/10.4103/0022-3859.57407] [PMID: 19884751]
[23]
Sandal G. Akbay Ş, Ozen M. Acquired Bartter-like syndrome association with netilmicin therapy in an extremely low birth weight infant. Ren Fail 2014; 36(1): 123-5.
[http://dx.doi.org/10.3109/0886022X.2013.832861] [PMID: 24059693]
[24]
Kamal Eldin T, Tosone G, Capuano A, Orlando R. Reversible hypokalemia and bartter-like syndrome during prolonged systemic therapy with colistimethate sodium in an adult patient. Drug Saf Case Rep 2017; 4(1): 10.
[http://dx.doi.org/10.1007/s40800-017-0052-1] [PMID: 28699114]
[25]
Colussi G, Rombolà G, Airaghi C, De Ferrari ME, Minetti L. Pseudo-Bartter’s syndrome from surreptitious diuretic intake: Differential diagnosis with true Bartter’s syndrome. Nephrol Dial Transplant 1992; 7(9): 896-901.
[http://dx.doi.org/10.1093/ndt/7.9.896]
[26]
Mitchell JE, Pomeroy C, Seppala M, Huber M. Pseudo-Bartter’s syndrome, diuretic abuse, idiopathic edema, and eating disorders. Int J Eat Disord 1988; 7: 225-37.
[http://dx.doi.org/10.1002/1098-108X(198803)7:2<225:AID-EAT2260070209>3.0.CO;2-2]
[27]
Dalugama C, Pathirage M, Kularatne SAM. Bartter syndrome-like phenotype in a patient with diabetes: A case report. J Med Case Reports 2018; 12(1): 222.
[http://dx.doi.org/10.1186/s13256-018-1752-6] [PMID: 30115098]
[28]
Casatta L, Ferraccioli GF, Bartoli E. Hypokalaemic alkalosis, acquired Gitelman’s and Bartter’s syndrome in chronic sialoadenitis. Br J Rheumatol 1997; 36(10): 1125-8.
[http://dx.doi.org/10.1093/rheumatology/36.10.1125] [PMID: 9374934]
[29]
Matsuura Y, Nomura N, Shoda W, et al. Tacrolimus ameliorates the phenotypes of type 4 Bartter syndrome model mice through activation of sodium-potassium-2 chloride cotransporter and sodium-chloride cotransporter. Biochem Biophys Res Commun 2019; 517(2): 364-8.
[http://dx.doi.org/10.1016/j.bbrc.2019.07.086] [PMID: 31362893]

Rights & Permissions Print Cite
Article Metrics
39
2
© 2024 Bentham Science Publishers | Privacy Policy